SM
Sabby Management Portfolio holdings
AUM
$13M
This Quarter Return
+2.36%
1 Year Return
-26.95%
3 Year Return
-56.43%
5 Year Return
-61.92%
10 Year Return
-71.17%
AUM
$186M
AUM Growth
–
Cap. Flow
+$186M
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
75.27%
Holding
107
New
46
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
AEGR
Aegerion Pharmaceuticals, Inc.
AEGR
|
$37.6M |
| 2 |
Sarepta Therapeutics
SRPT
|
$17.3M |
| 3 |
AbbVie
ABBV
|
$14.7M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$14.6M |
| 5 |
Zoetis
ZTS
|
$14.2M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 86.27% |
| 2 | Energy | 0.58% |
| 3 | Consumer Staples | 0% |
| 4 | Industrials | 0% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AEGR
1
DELISTED
Aegerion Pharmaceuticals, Inc.
AEGR
| $37.6M | 2.51% | +593,862 | New | +$37.6M |
|
|
2
Sarepta Therapeutics
SRPT
$1.78B
| $17.3M | 1.16% | +454,899 | New | +$17.3M |
|
|
3
AbbVie
ABBV
$372B
| $14.7M | 0.98% | +355,626 | New | +$14.7M |
|
|
4
Acadia Pharmaceuticals
ACAD
$4.38B
| $14.6M | 0.97% | +804,255 | New | +$14.6M |
|
|
5
Zoetis
ZTS
$69.3B
| $14.2M | 0.95% | +460,030 | New | +$14.2M |
|
6
iShares 20+ Year Treasury Bond ETF
TLT
$47.8B
| $11.5M | 0.77% | +104,050 | New | +$11.5M |
|
7
Gilead Sciences
GILD
$140B
| $8.92M | 0.6% | +174,108 | New | +$8.92M |
|
|
CYBX
8
DELISTED
CYBERONICS INC
CYBX
| $8.45M | 0.56% | +162,625 | New | +$8.45M |
|
|
ANTH
9
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
| $7.07M | 0.47% | +15,259,074 | New | +$7.07M |
|
|
KERX
10
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $5.57M | 0.37% | +745,435 | New | +$5.57M |
|
11
Arrowhead Research
ARWR
$3.05B
| $4.55M | 0.3% | +2,276,980 | New | +$4.55M |
|
12
Achieve Life Sciences
ACHV
$152M
| $3.89M | 0.26% | +396,730 | New | +$3.89M |
|
13
Savara
SVRA
$567M
| $3.31M | 0.22% | +7,711,867 | New | +$3.31M |
|
|
EDAP
14
EDAP TMS
EDAP
$84.5M
| $3.27M | 0.22% | +1,197,086 | New | +$3.27M |
|
|
NWBO
15
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
| $2.91M | 0.19% | +870,543 | New | +$2.91M |
|
16
CASI Pharmaceuticals
CASI
$35.8M
| $2.37M | 0.16% | +1,172,590 | New | +$2.37M |
|
|
MDVN
17
DELISTED
MEDIVATION, INC.
MDVN
| $2.36M | 0.16% | +47,900 | New | +$2.36M |
|
18
Assembly Biosciences
ASMB
$190M
| $1.67M | 0.11% | +695,400 | New | +$1.67M |
|
|
GNMX
19
DELISTED
Aevi Genomic Medicine, Inc.
GNMX
| $1.63M | 0.11% | +427,684 | New | +$1.63M |
|
|
AMRN
20
Amarin Corp
AMRN
$311M
| $1.46M | 0.1% | +251,271 | New | +$1.46M |
|
|
ORKA
21
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $1.28M | 0.09% | +988,934 | New | +$1.28M |
|
22
Vertex Pharmaceuticals
VRTX
$100B
| $1.21M | 0.08% | +15,108 | New | +$1.21M |
|
|
CEMP
23
DELISTED
Cempra, Inc.
CEMP
| $1.18M | 0.08% | +150,000 | New | +$1.18M |
|
|
AVNR
24
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
| $1.15M | 0.08% | +250,000 | New | +$1.15M |
|
|
RPRX
25
DELISTED
Repros Therapeutics Inc.
RPRX
| $1.15M | 0.08% | +62,090 | New | +$1.15M |
|